• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . SARS-CoV-2 human challenge reveals biomarkers that discriminate early and late phases of respiratory viral infections

tetano

Editor, Senior Moderator
Nat Commun


. 2024 Nov 30;15(1):10434.
doi: 10.1038/s41467-024-54764-3. SARS-CoV-2 human challenge reveals biomarkers that discriminate early and late phases of respiratory viral infections

Joshua Rosenheim[SUP] 1 [/SUP], Rishi K Gupta[SUP] 2 3 [/SUP], Clare Thakker[SUP] 1 [/SUP], Tiffeney Mann[SUP] 1 [/SUP], Lucy C K Bell[SUP] 1 [/SUP], Claire M Broderick[SUP] 4 [/SUP], Kieran Madon[SUP] 5 [/SUP], Loukas Papargyris[SUP] 4 [/SUP], Pete Dayananda[SUP] 4 [/SUP], Andrew J Kwok[SUP] 6 7 [/SUP], James Greenan-Barrett[SUP] 3 [/SUP], Helen R Wagstaffe[SUP] 4 [/SUP], Emily Conibear[SUP] 5 [/SUP], Joe Fenn[SUP] 5 [/SUP], Seran Hakki[SUP] 5 [/SUP], Rik G H Lindeboom[SUP] 8 [/SUP], Lisa M Dratva[SUP] 9 10 [/SUP], Briac Lemetais[SUP] 1 [/SUP], Caroline M Weight[SUP] 1 [/SUP], Cristina Venturini[SUP] 11 [/SUP], Myrsini Kaforou[SUP] 4 [/SUP], Michael Levin[SUP] 4 [/SUP], Mariya Kalinova[SUP] 12 [/SUP], Alex J Mann[SUP] 12 [/SUP], Andrew Catchpole[SUP] 12 [/SUP], Julian C Knight[SUP] 6 [/SUP], Marko Z Nikolić[SUP] 3 13 [/SUP], Sarah A Teichmann[SUP] 9 10 [/SUP], Ben Killingley[SUP] 14 [/SUP], Wendy Barclay[SUP] 4 [/SUP], Benjamin M Chain[SUP] 1 [/SUP], Ajit Lalvani[SUP] 5 [/SUP], Robert S Heyderman[SUP] 1 [/SUP], Christopher Chiu[SUP] 4 [/SUP], Mahdad Noursadeghi[SUP] 15 [/SUP]



Affiliations
Abstract

Blood transcriptional biomarkers of acute viral infections typically reflect type 1 interferon (IFN) signalling, but it is not known whether there are biological differences in their regulation that can be leveraged for distinct translational applications. We use high frequency sampling in the SARS-CoV-2 human challenge model to show induction of IFN-stimulated gene (ISG) expression with different temporal and cellular profiles. MX1 gene expression correlates with a rapid and transient wave of ISG expression across all cell types, which may precede PCR detection of replicative infection. Another ISG, IFI27, shows a delayed but sustained response restricted to myeloid cells, attributable to gene and cell-specific epigenetic regulation. These findings are reproducible in experimental and naturally acquired infections with influenza, respiratory syncytial virus and rhinovirus. Blood MX1 expression is superior to IFI27 expression for diagnosis of early infection, as a correlate of viral load and for discrimination of virus culture positivity. Therefore, MX1 expression offers potential to stratify patients for antiviral therapy or infection control interventions. Blood IFI27 expression is superior to MX1 expression for diagnostic accuracy across the time course of symptomatic infection and thereby, offers higher diagnostic yield for respiratory virus infections that incur a delay between transmission and testing.


 
Back
Top Bottom